ESMO 2018 | The challenges of treatment sequencing in HR+ breast cancer patients
Ahmed Saadeddin, MD, FRCR, of the King Saud Bin AbdulAziz University for Health Sciences, Riyadh, Saudi Arabia, addresses the challenges associated with sequencing treatments for HR+ breast cancer patients. Dr Saadeddin raises questions that are yet to be answered surrounding determining the best treatment strategies for patients when a variety of different combination and monotherapies are becoming more available. Can fulvestrant be effective as a monotherapy? And when should combination therapy be considered in the treatment course? This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.
Get great new content delivered to your inboxSign up